Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar 20;8(1):139.
doi: 10.3390/vaccines8010139.

Recent Progress on the Versatility of Virus-Like Particles

Affiliations
Review

Recent Progress on the Versatility of Virus-Like Particles

Ciying Qian et al. Vaccines (Basel). .

Abstract

Virus-like particles (VLPs) are multimeric nanostructures composed of one or more structural proteins of a virus in the absence of genetic material. Having similar morphology to natural viruses but lacking any pathogenicity or infectivity, VLPs have gradually become a safe substitute for inactivated or attenuated vaccines. VLPs can achieve tissue-specific targeting and complete and effective cell penetration. With highly ordered epitope repeats, VLPs have excellent immunogenicity and can induce strong cellular and humoral immune responses. In addition, as a type of nanocarrier, VLPs can be used to display antigenic epitopes or deliver small molecules. VLPs have thus become powerful tools for vaccinology and biomedical research. This review highlights the versatility of VLPs in antigen presentation, drug delivery, and vaccine technology.

Keywords: nanocarrier; recombinant vaccine; virus-like particles.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
An overview of virus-like particles (VLPs) used as efficient nanocarriers for antigen presentation, cargo delivery, and as a vaccine platform.
Figure 2
Figure 2
Non-enveloped and enveloped VLPs as a platform for antigen presentation and cargo delivery. The internal cavity of the VLPs accommodates exogenous oligonucleotides (rendered as brown gene-like patches), drug molecules (red circle), and small proteins (green pentagram) that can be delivered after the VLPs get the target organs or cells. The outer surface of the VLPs displays foreign proteins that are fused (red triangle) or covalently conjugated (yellow-green circle) to the particles.

References

    1. Standaert B., Rappuoli R. How comprehensive can we be in the economic assessment of vaccines? J. Mark. Access Health Policy. 2017;5:1336044. doi: 10.1080/20016689.2017.1336044. - DOI - PMC - PubMed
    1. Vetter V., Denizer G., Friedland L.R. Understanding modern-day vaccines: What you need to know. Ann. Med. 2018;50:110–120. doi: 10.1080/07853890.2017.1407035. - DOI - PubMed
    1. Tretyakova I., Plante K.S., Rossi S.L. Venezuelan equine encephalitis vaccine with rearranged genome resists reversion and protects non-human primates from viremia after aerosol challenge. Vaccine. 2020 doi: 10.1016/j.vaccine.2020.02.007. - DOI - PubMed
    1. Tebbens R.J., Pallansch M.A., Kew O.M. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Anal. 2006;26:1471–1505. doi: 10.1111/j.1539-6924.2006.00827.x. - DOI - PubMed
    1. Metz S.W., Thomas A., White L. Dengue virus-like particles mimic the antigenic properties of the infectious dengue virus envelope. Virol. J. 2018;15:60. doi: 10.1186/s12985-018-0970-2. - DOI - PMC - PubMed

LinkOut - more resources